MorphoSys and Galapagos’ Eczema Drug Abandoned at Phase II

Update: US District Court Rules Against MorphoSys’ Cancer Immunotherapy Patents

Can MorphoSys’ Alzheimer’s Treatment Work Where Big Pharma has Failed?

Morphosys and Galapagos Announce Positive Phase I Results for Atopic Dermatitis Treatment

ADVERTISEMENT

Update: After 25 years, MorphoSys Gets its First Antibody Approved

MorphoSys’ First Lanthipeptide Completes Phase I Successfully

Interview 12 Apr 2017

Video Interview: How Morphosys Grew Into a Billion-Euro Biotech

Can Roche & MorphoSys beat the odds in new Alzheimer’s Phase III Trials?

‘Disappointing results’ for Novartis & MorphoSys phase III in Muscle Disease

Inside Biotech’s Most Secretive Elite Conference: MorphoSys Talks on Investor Speed Dating in California

Exclusive from BIO-Europe 2015: Interview of Simon Moroney, CEO of leading German Biotech MorphoSys